依托三酯
医学
塞来昔布
沃马克
骨关节炎
荟萃分析
科克伦图书馆
双氯芬酸
物理疗法
对乙酰氨基酚
子群分析
梅德林
内科学
麻醉
替代医学
法学
病理
政治学
作者
Sun‐Young Jung,Eun Jin Jang,Seoung Wan Nam,Hyuk Hee Kwon,Seul Gi Im,Dam Kim,Soo-Kyung Cho,Dalho Kim,Yoon‐Kyoung Sung
标识
DOI:10.1080/14397595.2018.1439694
摘要
Objectives: To explore the relative efficacy of oral pharmacologic interventions in the treatment of knee OA. Methods: A systematic literature review was conducted using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases to identify trials conducted in patients with knee OA with a minimum 6 weeks of follow-up. The standardized mean differences of the change from baseline to week 6 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain between the treatment groups were estimated using Bayesian random-effects network meta-analyses. Subgroup analyses of baseline pain status (high, pain score ≥60 mm; low, pain score <60 mm) were performed. Results: Of 4067 manuscripts, 44 were included in the evidence synthesis. Etoricoxib had the highest ranking for improving WOMAC pain (probability of being top ranked, p (best) = .43) followed by naproxen (p (best) = .12), acetaminophen (AAP) (p (best) = .04), and celecoxib (p (best) = .02). The top three ranked interventions were etoricoxib, celecoxib and aceclofenac in the higher pain group, and tramadol, celecoxib, and diclofenac in the lower pain group. Conclusion: In the overall analysis, etoricoxib, celecoxib, and aceclofenac had the highest rankings for improving WOMAC pain. The ability to improve knee OA symptoms may differ depending on baseline pain and radiologic features.
科研通智能强力驱动
Strongly Powered by AbleSci AI